nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ORM1—saliva—nicotine dependence	0.0538	0.128	CbGeAlD
Gefitinib—SBK1—midbrain—nicotine dependence	0.0283	0.0675	CbGeAlD
Gefitinib—Gastric ulcer—Varenicline—nicotine dependence	0.0257	0.0639	CcSEcCtD
Gefitinib—MKNK2—cardiovascular system—nicotine dependence	0.0184	0.0438	CbGeAlD
Gefitinib—MKNK1—cardiovascular system—nicotine dependence	0.0182	0.0432	CbGeAlD
Gefitinib—SBK1—brain—nicotine dependence	0.0178	0.0424	CbGeAlD
Gefitinib—Acne—Varenicline—nicotine dependence	0.0178	0.0441	CcSEcCtD
Gefitinib—HIPK4—brain—nicotine dependence	0.0176	0.0419	CbGeAlD
Gefitinib—Tenderness—Varenicline—nicotine dependence	0.0171	0.0426	CcSEcCtD
Gefitinib—CSNK1E—midbrain—nicotine dependence	0.0157	0.0373	CbGeAlD
Gefitinib—CHEK2—brain—nicotine dependence	0.0155	0.0369	CbGeAlD
Gefitinib—ERBB3—midbrain—nicotine dependence	0.0151	0.036	CbGeAlD
Gefitinib—STK10—cardiovascular system—nicotine dependence	0.015	0.0356	CbGeAlD
Gefitinib—MKNK2—midbrain—nicotine dependence	0.0144	0.0342	CbGeAlD
Gefitinib—IRAK1—midbrain—nicotine dependence	0.0144	0.0342	CbGeAlD
Gefitinib—MKNK1—midbrain—nicotine dependence	0.0142	0.0338	CbGeAlD
Gefitinib—EPHA6—brain—nicotine dependence	0.0139	0.0331	CbGeAlD
Gefitinib—Dry eye—Varenicline—nicotine dependence	0.0138	0.0343	CcSEcCtD
Gefitinib—Mouth ulceration—Varenicline—nicotine dependence	0.0135	0.0336	CcSEcCtD
Gefitinib—MAP2K5—cardiovascular system—nicotine dependence	0.0134	0.0318	CbGeAlD
Gefitinib—MAP3K19—brain—nicotine dependence	0.0126	0.0301	CbGeAlD
Gefitinib—Eye pain—Varenicline—nicotine dependence	0.012	0.0299	CcSEcCtD
Gefitinib—Atrial fibrillation—Varenicline—nicotine dependence	0.0114	0.0285	CcSEcCtD
Gefitinib—Minaprine—DRD2—nicotine dependence	0.0107	0.397	CrCbGaD
Gefitinib—MAP2K5—midbrain—nicotine dependence	0.0104	0.0248	CbGeAlD
Gefitinib—EGFR—brain—nicotine dependence	0.0102	0.0244	CbGeAlD
Gefitinib—Dry skin—Varenicline—nicotine dependence	0.00994	0.0247	CcSEcCtD
Gefitinib—Hypokalaemia—Varenicline—nicotine dependence	0.00987	0.0245	CcSEcCtD
Gefitinib—CSNK1E—brain—nicotine dependence	0.00984	0.0234	CbGeAlD
Gefitinib—IRAK4—brain—nicotine dependence	0.00968	0.0231	CbGeAlD
Gefitinib—ERBB3—brain—nicotine dependence	0.00949	0.0226	CbGeAlD
Gefitinib—MKNK2—brain—nicotine dependence	0.00903	0.0215	CbGeAlD
Gefitinib—IRAK1—brain—nicotine dependence	0.00903	0.0215	CbGeAlD
Gefitinib—MKNK1—brain—nicotine dependence	0.00891	0.0212	CbGeAlD
Gefitinib—Cisapride—DRD2—nicotine dependence	0.00842	0.314	CrCbGaD
Gefitinib—Infestation—Varenicline—nicotine dependence	0.00836	0.0208	CcSEcCtD
Gefitinib—Infestation NOS—Varenicline—nicotine dependence	0.00836	0.0208	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00828	0.0206	CcSEcCtD
Gefitinib—Stomatitis—Varenicline—nicotine dependence	0.00814	0.0203	CcSEcCtD
Gefitinib—Conjunctivitis—Varenicline—nicotine dependence	0.00812	0.0202	CcSEcCtD
Gefitinib—Hepatobiliary disease—Varenicline—nicotine dependence	0.0079	0.0197	CcSEcCtD
Gefitinib—Epistaxis—Varenicline—nicotine dependence	0.00788	0.0196	CcSEcCtD
Gefitinib—Iloperidone—DRD2—nicotine dependence	0.00777	0.289	CrCbGaD
Gefitinib—Urinary tract disorder—Varenicline—nicotine dependence	0.00741	0.0184	CcSEcCtD
Gefitinib—Oedema peripheral—Varenicline—nicotine dependence	0.00739	0.0184	CcSEcCtD
Gefitinib—Urethral disorder—Varenicline—nicotine dependence	0.00735	0.0183	CcSEcCtD
Gefitinib—STK10—brain—nicotine dependence	0.00734	0.0175	CbGeAlD
Gefitinib—Erythema multiforme—Varenicline—nicotine dependence	0.00709	0.0176	CcSEcCtD
Gefitinib—Eye disorder—Varenicline—nicotine dependence	0.00701	0.0174	CcSEcCtD
Gefitinib—Cardiac disorder—Varenicline—nicotine dependence	0.00696	0.0173	CcSEcCtD
Gefitinib—Angiopathy—Varenicline—nicotine dependence	0.00681	0.0169	CcSEcCtD
Gefitinib—Mediastinal disorder—Varenicline—nicotine dependence	0.00676	0.0168	CcSEcCtD
Gefitinib—Arrhythmia—Varenicline—nicotine dependence	0.0067	0.0167	CcSEcCtD
Gefitinib—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0067	0.0443	CbGpPWpGaD
Gefitinib—MAP2K5—brain—nicotine dependence	0.00655	0.0156	CbGeAlD
Gefitinib—Malnutrition—Varenicline—nicotine dependence	0.00653	0.0162	CcSEcCtD
Gefitinib—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00616	0.0408	CbGpPWpGaD
Gefitinib—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00611	0.0404	CbGpPWpGaD
Gefitinib—Anaemia—Varenicline—nicotine dependence	0.00604	0.015	CcSEcCtD
Gefitinib—Angioedema—Varenicline—nicotine dependence	0.00597	0.0148	CcSEcCtD
Gefitinib—CYP2C9—cardiovascular system—nicotine dependence	0.00594	0.0141	CbGeAlD
Gefitinib—Malaise—Varenicline—nicotine dependence	0.00589	0.0146	CcSEcCtD
Gefitinib—Cough—Varenicline—nicotine dependence	0.0057	0.0142	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00552	0.0137	CcSEcCtD
Gefitinib—Dry mouth—Varenicline—nicotine dependence	0.00544	0.0135	CcSEcCtD
Gefitinib—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00537	0.0355	CbGpPWpGaD
Gefitinib—Infection—Varenicline—nicotine dependence	0.00529	0.0132	CcSEcCtD
Gefitinib—Shock—Varenicline—nicotine dependence	0.00524	0.013	CcSEcCtD
Gefitinib—Nervous system disorder—Varenicline—nicotine dependence	0.00523	0.013	CcSEcCtD
Gefitinib—Thrombocytopenia—Varenicline—nicotine dependence	0.00522	0.013	CcSEcCtD
Gefitinib—Skin disorder—Varenicline—nicotine dependence	0.00518	0.0129	CcSEcCtD
Gefitinib—Anorexia—Varenicline—nicotine dependence	0.00508	0.0126	CcSEcCtD
Gefitinib—ABCG2—midbrain—nicotine dependence	0.00507	0.0121	CbGeAlD
Gefitinib—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.00507	0.0336	CbGpPWpGaD
Gefitinib—Hypotension—Varenicline—nicotine dependence	0.00498	0.0124	CcSEcCtD
Gefitinib—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00481	0.0318	CbGpPWpGaD
Gefitinib—Dyspnoea—Varenicline—nicotine dependence	0.00475	0.0118	CcSEcCtD
Gefitinib—IRAK1—p75 NTR receptor-mediated signalling—FGD1—nicotine dependence	0.00473	0.0313	CbGpPWpGaD
Gefitinib—ALB—brain—nicotine dependence	0.00467	0.0111	CbGeAlD
Gefitinib—Decreased appetite—Varenicline—nicotine dependence	0.00463	0.0115	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.0046	0.0114	CcSEcCtD
Gefitinib—Fatigue—Varenicline—nicotine dependence	0.00459	0.0114	CcSEcCtD
Gefitinib—Pain—Varenicline—nicotine dependence	0.00456	0.0113	CcSEcCtD
Gefitinib—Constipation—Varenicline—nicotine dependence	0.00456	0.0113	CcSEcCtD
Gefitinib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00436	0.0108	CcSEcCtD
Gefitinib—Urticaria—Varenicline—nicotine dependence	0.00423	0.0105	CcSEcCtD
Gefitinib—Body temperature increased—Varenicline—nicotine dependence	0.00421	0.0105	CcSEcCtD
Gefitinib—Abdominal pain—Varenicline—nicotine dependence	0.00421	0.0105	CcSEcCtD
Gefitinib—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00415	0.0275	CbGpPWpGaD
Gefitinib—Hypersensitivity—Varenicline—nicotine dependence	0.00393	0.00976	CcSEcCtD
Gefitinib—Asthenia—Varenicline—nicotine dependence	0.00382	0.00951	CcSEcCtD
Gefitinib—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00382	0.0253	CbGpPWpGaD
Gefitinib—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00378	0.0251	CbGpPWpGaD
Gefitinib—Pruritus—Varenicline—nicotine dependence	0.00377	0.00938	CcSEcCtD
Gefitinib—Diarrhoea—Varenicline—nicotine dependence	0.00365	0.00907	CcSEcCtD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00364	0.0241	CbGpPWpGaD
Gefitinib—Vomiting—Varenicline—nicotine dependence	0.00339	0.00843	CcSEcCtD
Gefitinib—Rash—Varenicline—nicotine dependence	0.00336	0.00836	CcSEcCtD
Gefitinib—Dermatitis—Varenicline—nicotine dependence	0.00336	0.00835	CcSEcCtD
Gefitinib—ABCB1—cardiovascular system—nicotine dependence	0.0032	0.00763	CbGeAlD
Gefitinib—ABCG2—brain—nicotine dependence	0.00319	0.00759	CbGeAlD
Gefitinib—Nausea—Varenicline—nicotine dependence	0.00317	0.00787	CcSEcCtD
Gefitinib—CYP1A1—brain—nicotine dependence	0.00303	0.00721	CbGeAlD
Gefitinib—MAP2K5—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00301	0.0199	CbGpPWpGaD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—DRD2—nicotine dependence	0.00269	0.0178	CbGpPWpGaD
Gefitinib—ABCB1—midbrain—nicotine dependence	0.0025	0.00596	CbGeAlD
Gefitinib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.0025	0.0165	CbGpPWpGaD
Gefitinib—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00223	0.0148	CbGpPWpGaD
Gefitinib—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0022	0.0146	CbGpPWpGaD
Gefitinib—CYP2D6—brain—nicotine dependence	0.00219	0.0052	CbGeAlD
Gefitinib—MAP2K5—Signaling by NGF—FGD1—nicotine dependence	0.00217	0.0144	CbGpPWpGaD
Gefitinib—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00211	0.0139	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—FGD1—nicotine dependence	0.00209	0.0138	CbGpPWpGaD
Gefitinib—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00208	0.0138	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00196	0.013	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00191	0.0127	CbGpPWpGaD
Gefitinib—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00181	0.012	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—FGD1—nicotine dependence	0.00174	0.0115	CbGpPWpGaD
Gefitinib—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00172	0.0114	CbGpPWpGaD
Gefitinib—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00171	0.0113	CbGpPWpGaD
Gefitinib—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0017	0.0113	CbGpPWpGaD
Gefitinib—EGFR—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00161	0.0107	CbGpPWpGaD
Gefitinib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00159	0.0105	CbGpPWpGaD
Gefitinib—ABCB1—brain—nicotine dependence	0.00157	0.00374	CbGeAlD
Gefitinib—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00157	0.0104	CbGpPWpGaD
Gefitinib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00156	0.0104	CbGpPWpGaD
Gefitinib—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00155	0.0103	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—DRD2—nicotine dependence	0.00141	0.00935	CbGpPWpGaD
Gefitinib—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0014	0.00925	CbGpPWpGaD
Gefitinib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00129	0.00851	CbGpPWpGaD
Gefitinib—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00127	0.00844	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00122	0.00808	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00117	0.00775	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—FGD1—nicotine dependence	0.00116	0.0077	CbGpPWpGaD
Gefitinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00104	0.00686	CbGpPWpGaD
Gefitinib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00102	0.00677	CbGpPWpGaD
Gefitinib—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00102	0.00674	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TAS2R16—nicotine dependence	0.000965	0.00639	CbGpPWpGaD
Gefitinib—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000962	0.00637	CbGpPWpGaD
Gefitinib—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00096	0.00636	CbGpPWpGaD
Gefitinib—MKNK1—Disease—AKR1B10—nicotine dependence	0.000956	0.00633	CbGpPWpGaD
Gefitinib—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000947	0.00627	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—WASF2—nicotine dependence	0.00093	0.00616	CbGpPWpGaD
Gefitinib—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.000907	0.00601	CbGpPWpGaD
Gefitinib—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000894	0.00592	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—WASF1—nicotine dependence	0.000892	0.00591	CbGpPWpGaD
Gefitinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00084	0.00556	CbGpPWpGaD
Gefitinib—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000787	0.00521	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—FGD1—nicotine dependence	0.000758	0.00502	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TAS2R16—nicotine dependence	0.000751	0.00497	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKR1B10—nicotine dependence	0.000743	0.00492	CbGpPWpGaD
Gefitinib—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000742	0.00491	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—WASF2—nicotine dependence	0.000742	0.00491	CbGpPWpGaD
Gefitinib—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000732	0.00485	CbGpPWpGaD
Gefitinib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000724	0.0048	CbGpPWpGaD
Gefitinib—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000718	0.00475	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—WASF1—nicotine dependence	0.000711	0.00471	CbGpPWpGaD
Gefitinib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000683	0.00452	CbGpPWpGaD
Gefitinib—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000677	0.00448	CbGpPWpGaD
Gefitinib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000673	0.00446	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKR1B10—nicotine dependence	0.000669	0.00443	CbGpPWpGaD
Gefitinib—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000667	0.00442	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—WASF2—nicotine dependence	0.000618	0.00409	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TAS2R16—nicotine dependence	0.000593	0.00393	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—WASF1—nicotine dependence	0.000592	0.00392	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FGD1—nicotine dependence	0.000589	0.0039	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TAS2R16—nicotine dependence	0.000572	0.00379	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKR1B10—nicotine dependence	0.000566	0.00375	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—WASF2—nicotine dependence	0.000542	0.00359	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—TAS2R16—nicotine dependence	0.000539	0.00357	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKR1B10—nicotine dependence	0.00052	0.00345	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—WASF1—nicotine dependence	0.00052	0.00344	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000489	0.00324	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TAS2R16—nicotine dependence	0.000476	0.00315	CbGpPWpGaD
Gefitinib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000473	0.00314	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—WASF2—nicotine dependence	0.000471	0.00312	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FGD1—nicotine dependence	0.000466	0.00308	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—WASF1—nicotine dependence	0.000452	0.00299	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FGD1—nicotine dependence	0.000449	0.00297	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000446	0.00296	CbGpPWpGaD
Gefitinib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00044	0.00291	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—WASF2—nicotine dependence	0.000432	0.00286	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—FGD1—nicotine dependence	0.000423	0.0028	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—WASF1—nicotine dependence	0.000414	0.00274	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—WASF2—nicotine dependence	0.000413	0.00273	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKR1B10—nicotine dependence	0.000411	0.00272	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—OPRM1—nicotine dependence	0.000407	0.00269	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKR1B10—nicotine dependence	0.000397	0.00263	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—WASF1—nicotine dependence	0.000396	0.00262	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FGD1—nicotine dependence	0.000374	0.00247	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—WASF2—nicotine dependence	0.000367	0.00243	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—WASF2—nicotine dependence	0.00036	0.00238	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—WASF1—nicotine dependence	0.000352	0.00233	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—WASF1—nicotine dependence	0.000345	0.00228	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKR1B10—nicotine dependence	0.00033	0.00219	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TAS2R16—nicotine dependence	0.000318	0.00211	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—OPRM1—nicotine dependence	0.000316	0.0021	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKR1B10—nicotine dependence	0.000315	0.00209	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000302	0.002	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—DRD2—nicotine dependence	0.000294	0.00195	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—WASF2—nicotine dependence	0.00029	0.00192	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—WASF2—nicotine dependence	0.000279	0.00185	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—WASF1—nicotine dependence	0.000278	0.00184	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—WASF1—nicotine dependence	0.000268	0.00177	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000264	0.00175	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—OPRM1—nicotine dependence	0.00025	0.00166	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGD1—nicotine dependence	0.00025	0.00165	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—OPRM1—nicotine dependence	0.000241	0.0016	CbGpPWpGaD
Gefitinib—EGFR—Immune System—WASF2—nicotine dependence	0.000241	0.00159	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—WASF2—nicotine dependence	0.000233	0.00154	CbGpPWpGaD
Gefitinib—EGFR—Immune System—WASF1—nicotine dependence	0.000231	0.00153	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000229	0.00152	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—DRD2—nicotine dependence	0.000229	0.00152	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—OPRM1—nicotine dependence	0.000227	0.0015	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—WASF1—nicotine dependence	0.000223	0.00148	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKR1B10—nicotine dependence	0.000221	0.00146	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—OPRM1—nicotine dependence	0.000201	0.00133	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—DRD2—nicotine dependence	0.000181	0.0012	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—DRD2—nicotine dependence	0.000174	0.00115	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—DRD2—nicotine dependence	0.000164	0.00109	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000164	0.00109	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—WASF2—nicotine dependence	0.000156	0.00103	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000155	0.00103	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—WASF1—nicotine dependence	0.000149	0.000987	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—DRD2—nicotine dependence	0.000145	0.000961	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP2A7—nicotine dependence	0.000141	0.000936	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—OPRM1—nicotine dependence	0.000134	0.000889	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000127	0.00084	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000124	0.00082	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000117	0.000773	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000116	0.000766	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—DRD2—nicotine dependence	9.71e-05	0.000643	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	7.63e-05	0.000505	CbGpPWpGaD
